AFYAConsumer Defensive · Education & Training ServicesThe 9 Wall Street analysts covering Afya Ltd. hold a median 12-month price target of $16 — +16.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 13 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Afya Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Revisions (39): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AFYA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +16.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 June 2026 | JP Morgan | Maintains | Neutral | $22 → $21 |
| 30 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Feb 2026 | B of A Securities | Downgrade | Neutral | — |
| 13 Feb 2026 | Morgan Stanley | Downgrade | Underweight | — |
| 16 Jan 2026 | UBS | Downgrade | Neutral | — |
| 8 Jan 2026 | UBS | Maintains | Buy | — |
| 7 Jan 2026 | JP Morgan | Downgrade | Neutral | — |
| 8 Sept 2025 | JP Morgan | Upgrade | Overweight | — |
| 8 Sept 2025 | UBS | Upgrade | Buy | — |
| 29 July 2025 | Citigroup | Upgrade | Neutral | — |
| 12 June 2025 | UBS | Maintains | Neutral | — |
| 11 Mar 2025 | Morgan Stanley | Downgrade | Underweight | — |
| 31 Jan 2025 | Citigroup | Downgrade | Sell | — |
| 17 Jan 2025 | JP Morgan | Maintains | Neutral | — |
| 3 Dec 2024 | Goldman Sachs | Initiates | Sell | — |
| 30 Aug 2024 | UBS | Initiates | Neutral | — |
| 21 June 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 22 Jan 2024 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 27 Nov 2023 | JP Morgan | Downgrade | Neutral | — |
| 13 Oct 2023 | Morgan Stanley | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AFYA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 62% of US stocks
Cheaper than 89% of US stocks
Cheaper than 65% of US stocks
Cheaper than 57% of US stocks
Higher than 48% of US stocks
Higher than 38% of US stocks
Higher than 82% of US stocks
Higher than 91% of US stocks
Higher than 82% of US stocks
Higher than 77% of US stocks
Higher than 88% of US stocks
Higher than 94% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Afya Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Afya (AFYA) reported Q2 earnings of $0.45 per share, below the Zacks Consensus Estimate of $0.46 per share, though up from $0.40 per share in the same quarter a year ago. Revenues also lagged estimates.
Why it matters — The results lagged analyst expectations for the quarter, which is a notable data point for those tracking AFYA's financial performance.
Afya reported first-half 2026 revenue of BRL 1.985 billion, up 7% year-over-year, with adjusted EBITDA up 3% to BRL 918 million. Net income rose 7% to BRL 463 million and basic earnings per share increased 9% to BRL 5.10, according to its Q2 earnings call highlights.
Why it matters — Afya watchers would note that the company sustained growth across revenue, EBITDA, net income, and earnings per share in the first half of 2026.
Afya Limited held its Q2 2026 earnings call, during which management discussed the company's financial results and operational performance for the quarter.
Why it matters — The earnings call provides investors and analysts with direct insight into Afya's recent financial health and management's perspective on the business.
Afya Limited announced its financial and operating results for the second quarter and first half of 2026, covering the period ended June 30, 2026. Results are expressed in Brazilian Reais and reported in accordance with IFRS.
Why it matters — This is Afya's regular periodic earnings disclosure, which AFYA watchers would review to assess the company's recent financial and operating performance.
Afya Limited announced that Marcelo Ken Suhara was appointed as Chair Member of its Audit, Risks and Ethics Committee on July 27, 2026. Suhara currently serves as an independent member of Afya's Board of Directors and a member of the Audit, Risks and Ethics Committee and the Audit Committee.
Why it matters — AFYA watchers would care because the appointment of a new chair for the Audit, Risks and Ethics Committee, particularly an existing independent board member, signals a change in the leadership of a key oversight function.
The 9 Wall Street analysts covering Afya Ltd. have a median 12-month price target of $16, with estimates ranging from $14 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Afya Ltd., 1 rate it a Buy, 5 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Afya Ltd. 67 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Afya Ltd. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +16.1% from the last close, and Ticker Nerd's factor model ranks Afya Ltd. 67 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Afya Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AFYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $21 over the next 12 months.
Afya Ltd. returned -6.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Afya Ltd. is a leading medical education group and provider of medical practice solutions in Brazil.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Afya (AFYA) Q2 Earnings and Revenues Lag Estimates". Afya (AFYA) reported Q2 earnings of $0.45 per share, below the Zacks Consensus Estimate of $0.46 per share, though up from $0.40 per share in the same quarter a year ago. Revenues also lagged estimates.
Afya Ltd. is a leading medical education group and provider of medical practice solutions in Brazil. It operates across three main segments: Undergrad, which delivers educational services through undergraduate courses in medicine, health sciences, and other non-health programs; Continuing Education, offering medical residency preparatory courses, graduate courses, and lifelong learning programs delivered via digital and in-person formats; and Digital Services, providing subscription-based mobile apps and website portals focused on clinical decision support, management tools, and enhancing doctor-patient relationships. Afya Ltd. supports physicians throughout their careers with an end-to-end ecosystem that includes access, demand generation, and efficiency solutions for healthcare providers. Its portfolio extends to courses in dentistry, nursing, law, engineering, psychology, accounting, and management, catering to a broad network of students, lifelong learners, and third-party medical schools. Headquartered in Belo Horizonte, Brazil, Afya Ltd. plays a pivotal role in Brazil's medical and healthcare education sectors by expanding medical school seats and fostering professional development in the physician-centric ecosystem.
9,395 employees · Brazil · https://www.afya.com.br